Oxycodone Drugs Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Type (Short-acting Oxycodone and Long-acting Oxycodone), By Dosage Form (Tablets, Capsules and Injections), By Indication (Neuropathic Pain, Musculoskeletal Pain, Cancer Pain, Post-operative Pain and Other Indications), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies) and Region

Oxycodone Drugs Market was valued at US$ 456.2 million in 2023 and is projected to grow at 5.1% CAGR from 2024-2030. Oxycodone is a powerful opioid medication used to manage severe pain that cannot be controlled with non-opioid medications. Oxycodone is used to treat moderate to severe pain, often after surgery, injury, or for chronic conditions where other pain medications are insufficient. This includes pain from conditions such as cancer, severe arthritis, or serious injuries. An increasing prevalence of chronic pain conditions, such as cancer and arthritis, boosts the demand for effective pain management solutions like Oxycodone. For instance, according to the CDC’s National Centre for Health Statistics, approximately 20% of U.S. adults experience chronic pain, with 7.4% experiencing pain that frequently limits daily activities (CDC, 2022). This high prevalence of chronic pain drives the demand for potent pain relief options like Oxycodone. Additionally, when more surgeries are performed, there is a greater need for oxycodone medications to treat postoperative pain, which fuels market expansion.

However, Oxycodone has a high potential for addiction and misuse, leading to regulatory restrictions and concerns over prescription practices. Furthermore, stringent regulations and guidelines on opioid prescriptions can limit market growth. Whereas, innovations in drug formulation to reduce abuse potential can expand market opportunities.

Key Developments

• In 2022: Oxaydo® was approved by FDA with features to deter abuse, such as a unique formulation that reduces the potential for misuse through inhalation or injection.
• In 2021: Xtampza ER® is an extended-release oxycodone product that incorporates abuse-deterrent technology. The FDA approved this formulation to reduce the potential for misuse and addiction.
• In 2020: The FDA approved a new formulation of OxyContin® designed to deter abuse. This formulation includes physical and chemical barriers that make it more difficult to crush or dissolve the medication for misuse.